Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | ACLY | P53396 | 3/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12228539 | 0.88 | NOD2 (0.44) | KMT2AMEN1PTGDRPTGDR2KDM4E | |
| SCHEMBL1999643 | 0.88 | KMT2A (0.39) | KMT2AMEN1PTGDRPTGDR2ACLY | |
| SCHEMBL14115940 | 0.88 | KMT2A (0.39) | KMT2AMEN1PTGDRPTGDR2ACLY | |
| SCHEMBL12228550 | 0.85 | KMT2A (0.37) | KMT2AMEN1PTGDRPTGDR2ACLY | |
| SCHEMBL12253381 | 0.81 | PTGDR (0.35) | KMT2AMEN1PTGDRPTGDR2ACLY | |
| SCHEMBL12229948 | 0.78 | PTGDR2 (0.35) | KMT2AMEN1PTGDRPTGDR2ACLY | |
| SCHEMBL12228600 | 0.77 | NOD2 (0.44) | KMT2AMEN1PTGDRPTGDR2KDM4E | |
| SCHEMBL14115908 | 0.77 | NOD2 (0.44) | KMT2AMEN1PTGDRPTGDR2KDM4E | |
| SCHEMBL12228582 | 0.76 | PTGDR2 (0.46) | KMT2AMEN1PTGDRPTGDR2ACLY | |
| SCHEMBL12228599 | 0.73 | NOD2 (0.41) | KMT2AMEN1PTGDRPTGDR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078029-B1 | ENANTIOMERICALLY PURE PHOSPHOINDOLE AS HIV INHIBITOR | IDENIX PHARMACEUTICALS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8486991-B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-7960428-B2 | (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester; Flaviviruses; bioavailability; pharmacokinetics | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | DUSP3, PNP, PPP5C | KMT2A 2307/4885MEN1 3674/4885PTGDR 3879/4885 |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | DUSP3, PNP, PPP5C | KMT2A 2307/4885MEN1 3674/4885PTGDR 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.